Sylvester Comprehensive Cancer Center

E-mail a Friend

Khaled A. Tolba, M.D.

General Information

Khaled A. Tolba, M.D.

Languages

  • English
  • Arabic

Certifications

  • American Board of Internal Med-Medical Oncology

CV

Specialties

  • Internal Medicine
  • Hematology/Oncology - Internal Medicine

Roles

  • Assistant Professor of Clinical Medicine

Clinical Interests

Head & neck and lung cancer

Education

Graduate
Cairo University School of Medicine
Residency
Tufts Medical School
Fellowship
University of Rochester

Publications

  • Hammer J, Valsasnini P, Tolba K, Bolin D, Higelin J, Takacs B, Sinigaglia F: Promiscuous and Allele-Specific Anchors in HLA-DR-Binding Peptides. Cell, 74, 197-203, 1993
  • Tolba K, Federoff HJ, Rosenblatt JD: Cancer Gene Therapy. In Rubin’s Clinical Oncology, 8th edition, 1998
  • Tolba K, Deliargyris E: Cardiotoxicity of Cancer Therapy. Cancer Investigation. 17, 408 – 422, July, 1999.
  • Mahmood K, Tolba K, Federoff HJ, Rosenblatt JD: The Role of HSV Amplicon Vectors in Cancer Gene Therapy. Gene Therapy and Molecular Biology, Vol. 4, 209-219, Dec.1999
  • Tolba K, Bowers WJ, Hilchey SP, Halterman MW, Howard DF, Giuliano RE, Federoff HJ and Rosenblatt JD. Development of HSV-1 Amplicon-based Immunotherapy for Chronic Lymphocytic Leukemia. Blood, July 15th, Volume 98, Number 2, 2001
  • Tolba K, Bowers W, Eling D, Casey A, Kipps T, Federoff H and Rosenblatt J. HSV amplicon-mediated delivery of LIGHT enhances the antigen-presenting capacity of chronic lymphocytic leukemia. Molecular Therapy 6:455, 2002.
  • Tolba K, Bowers WJ, Muller J, Housekneckt V, Giuliano RE, Federoff HJ and Rosenblatt JD. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity. Cancer Research 62:6545-6551, 2002.
  • Rosenblatt JD, Shin SU, Nechustan H, Yi KH, Tolba, K. Potential role of chemokines in immune therapy of cancer. Israel Med Assoc J 4(11): 1054-9, 2002.
  • Raez LE, Santos ES, Lopes G, Rosado MF, Negret LM, Rocha-Lima C, Tolba K, Farfan N, Hamilton-Nelson K, Silva O, Roman E. Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer. 2006 Sep;53(3):347-53.
  • Lindner I, Torruellas-Garcia J, Kolonias D, Carlson LM, Tolba KA, Plano GV, Lee KP. Modulation of dendritic cell differentiation and function by YopJ of Yersinia pestis. Eur J Immunol. 2007 Sep;37(9):2450-62. Erratum in: Eur J Immunol. 2007 Oct;37(10):2991
  • Yi KH, Nechushtan H, Bowers WJ, Walker GR, Zhang Y, Pham DG, Podack ER, Federoff HJ, Tolba K, Rosenblatt JD. Adoptively transferred tumor-specific T cells stimulated ex-vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo. Cancer Research. 2007 Oct 15; 67(20):10027-37.
  • Yi KH, Nechushtan H, Bowers WJ, Walker GR, Zhang Y, Pham DG, Podack ER, Federoff HJ, Tolba K, Rosenblatt JD. Adoptively transferred tumor-specific T cells stimulated ex-vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo. Cancer Research. 2007 Oct 15; 67(20):10027-37.
  • Nechushtan H, Pham D, Zhang Y, Morgensztern D, Yi KH, Shin SU, Federoff HJ, Bowers WJ, Tolba K, Rosenblatt JD. Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction. Cancer Immunol Immunother. 2008 May;57(5):663-75.
  • Daubeuf S, Singh D, Tan Y, Bowers WJ, Federoff HJ, Tolba, K. HSV ICP0 Recruits USP7 to modulate TLR-mediated Innate Response. Blood 2009;113:3264-3275.
  • Bastos BR, Hatoum GF, Walker GR, Tolba K, Takita C, Gomez J, Santos ES, Lopes G, Raez LE. Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2010 Apr;5(4):533-9.
  • Cho HM, Rosenblatt JD, Tolba K, Shin SJ, Shin DS, Calfa C, Zhang Y, Shin SU. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response. Cancer Research, 2010 Dec 15; 70(24):10121-30.
  • Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, Kroll S, Jung DT, Kurtoglu M, Rosenblatt J, Lampidis TJ : A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Feb; 71(2):523-30. Epub 2012 Dec 11.
  • Luis E. Raez, Gail R. Walker, Paulette Baldie, Eva Fisher, Jorge E. Gomez, Khaled Tolba, Edgardo S. Santos, Eckhard R. Podack. CD8 T cell response in a phase I study of therapeutic vaccination of advanced NSCLC with allogeneic tumor cells secreting endoplasmic reticulum-chaperone gp96-Ig-peptide complexes. Advances in Lung Cancer, Vol. 2, No.1, 9-18 (2013).
  • Saigal K, Santos ES, Tolba K, Kwon D, Elsayyad N, Abramowitz MC, Mandalia A, Samuels MA. : Concurrent radiotherapy with Carboplatin and cetuximab for the treatment of medically compromised patients with locoregionally advanced head and neck squamous cell carcinoma. Front Oncol. 2014 Jun 30; 4:165.
  • Harold J. Wanebo, Ju-Whei Lee, Barbara A. Burtness, John A. Ridge, Musie Ghebremichael, Sharon A. Spencer, M.D., Diamando Psyrri, Eirini Pectasides, David Rimm, Fred R. Rosen, Mark R. Hancock, Khaled A. Tolba, Arlene A. Forastiere: Induction cetuximab, paclitaxel and carboplatin followed by chemoradiation with cetuximab, paclitaxel and carboplatin for stage III/IV head and neck squamous cancer: A Phase II ECOG-ACRIN trial (E2303). Ann Oncology, July 9th 2014, Epub ahead of print.

E-mail a Friend